Business, energy, technology, markets and global industry news from Business News Today

Obsidian Therapeutics

PharmaDeviceNews Obsidian Therapeutics
Obsidian Therapeutics’ $350 million financing and Galera Therapeutics merger place its OBX-115 engineered cell therapy program at the centre of the newly listed biotechnology company’s growth strategy. Representative image.
Pharma & Biotech

What the Obsidian Therapeutics and Galera Therapeutics merger means for OBX-115

Obsidian Therapeutics closes its Galera merger and $350 million financing, putting OBX-115 melanoma data and execution under investor scrutiny.

Read More
Pharma & Biotech

Obsidian Therapeutics puts OBX-115 in the spotlight, but is this a real melanoma cell therapy inflection point?

Obsidian Therapeutics will present OBX-115 melanoma data at ASCO 2026. Read why the update matters for TIL therapy, scalability, and solid tumor strategy.

Read More